India Active Pharmaceutical Ingredient (API) Market - Forecast and Analysis, 2024-2028

The India active pharmaceutical ingredient market size is estimated to grow by USD 7.56 billion, at a CAGR of 6.49% between 2023 and 2028. The market research and growth report also includes an in-depth analysis of drivers, trends, and challenges.

Originally published on Technavio: India Active Pharmaceutical Ingredient (API) Market by Manufacturing Type, Type, and Product Type - Forecast and Analysis 2024-2028

The India Active Pharmaceutical Ingredient (API) Market is anticipated to undergo significant growth from 2024 to 2028, driven by various factors including increasing demand for generic drugs, a favorable regulatory environment, and the country's cost-effective manufacturing capabilities. This analysis focuses on different aspects of the market, including manufacturing type, type of API, and product type, to provide insights into market size, trends, and forecasts.

In terms of manufacturing type, India's API market comprises both captive manufacturing and contract manufacturing segments. Captive manufacturing refers to API production by pharmaceutical companies for their own use, while contract manufacturing involves outsourcing API production to third-party manufacturers. The country's robust contract manufacturing infrastructure, coupled with its skilled workforce and cost advantages, makes it an attractive destination for both domestic and international pharmaceutical companies seeking API manufacturing services.

The type of API encompasses various categories such as synthetic APIs, biotech APIs, and others. Synthetic APIs, which are chemically synthesized, dominate the Indian API market due to their widespread use in pharmaceutical formulations. However, there is a growing demand for biotech APIs, driven by advancements in biotechnology and the development of biopharmaceuticals. India's expertise in biotechnology and biosimilars positions it as a key player in the global biotech API market.

Furthermore, the product type segment includes various categories of APIs such as branded APIs, generic APIs, and over-the-counter (OTC) APIs. Branded APIs are proprietary molecules developed and marketed by pharmaceutical companies, while generic APIs are non-branded versions of existing drugs. India is a major supplier of generic APIs to global markets, owing to its competitive manufacturing costs and regulatory compliance. Additionally, OTC APIs, which are used in the production of over-the-counter medications, contribute to the diversity of India's API market.

Key players in the India API market include both domestic and multinational pharmaceutical companies, as well as contract manufacturing organizations (CMOs). These companies specialize in the production of a wide range of APIs catering to various therapeutic areas such as cardiovascular, oncology, central nervous system, and others. Strategic initiatives such as investments in research and development, capacity expansion, and partnerships with global pharmaceutical companies are driving market competitiveness and innovation in India's API industry.

To Learn deeper into this report View Sample PDF

Looking ahead, the India API market is expected to witness continued growth driven by factors such as increasing demand for pharmaceuticals, patent expirations of blockbuster drugs, and the country's expanding capabilities in complex API manufacturing. Moreover, government initiatives such as the 'Make in India' campaign and regulatory reforms aimed at streamlining approval processes and ensuring quality compliance are expected to further support market growth. Overall, the forecast period presents opportunities for India to strengthen its position as a leading API manufacturer and supplier in the global pharmaceutical industry.

For more information please contact.

Technavio Research

Jesse Maida

Media Marketing Executive

US: +1 844 364 1100

UK: +44 203 893 3200

Email: [email protected]



164 Blog posts